{
    "nct_id": "NCT03895203",
    "official_title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis",
    "inclusion_criteria": "* An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form is signed and dated by the subject\n* Subject is male or female at least 18 years of age\n* Female subject must be postmenopausal, permanently sterilized or willing to use a highly effective method of contraception\n* Documented diagnosis of adult-onset Psoriatic Arthritis (PsA) meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 6 months prior to Screening with active PsA and must have at Baseline tender joint count (TJC) >=3 out of 68 and swollen joint count (SJC) >=3 out of 66\n* Subject must be negative for rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies\n* Subject must have at least 1 active psoriatic lesion(s) and/or a documented history of psoriasis (PSO)\n* Subject must be a suitable candidate for treatment with adalimumab and has no contraindications to receive adalimumab as per the local label as assessed by the Investigator\n* Subjects currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics (including mild opioids), corticosteroids, methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study\n* Subjects with current or prior exposure to any biologics for the treatment of Psoriatic Arthritis (PsA) or Psoriasis (PSO)\n* Subject has an active infection or a history of recent serious infections\n* Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection\n* Subject has a diagnosis of inflammatory conditions other than PSO or PsA. Subjects with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease at Screening or Baseline\n* Subject had acute anterior uveitis within 6 weeks of Baseline\n* Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer\n* Subject has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic and guttate PSO, or drug-induced PSO)\n* Presence of active suicidal ideation, or moderately severe major depression or severe major depression\n* Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening",
    "miscellaneous_criteria": ""
}